169 related articles for article (PubMed ID: 38627714)
21. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
22. Identification of subclusters and prognostic genes based on glycolysis/gluconeogenesis in hepatocellular carcinoma.
Chen D; Aierken A; Li H; Chen R; Ren L; Wang K
Front Immunol; 2023; 14():1232390. PubMed ID: 37881434
[TBL] [Abstract][Full Text] [Related]
23. A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients.
Liu T; Chen X; Peng B; Liang C; Zhang H; Wang S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10255-10267. PubMed ID: 37269346
[TBL] [Abstract][Full Text] [Related]
24. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
25. The impact of liver fibrosis on the progression of hepatocellular carcinoma via a hypoxia-immune-integrated prognostic model.
Li Q; Zhang J; Xiao S; Hu M; Cheng J; Yao C; Zhuang Q
Int Immunopharmacol; 2023 Dec; 125(Pt A):111136. PubMed ID: 37935090
[TBL] [Abstract][Full Text] [Related]
26. Transcriptome analysis reveals the prognostic and immune infiltration characteristics of glycolysis and hypoxia in head and neck squamous cell carcinoma.
Liu J; Lu J; Li W
BMC Cancer; 2022 Mar; 22(1):352. PubMed ID: 35361159
[TBL] [Abstract][Full Text] [Related]
27. Construction and validation of 3-genes hypoxia-related prognostic signature to predict the prognosis and therapeutic response of hepatocellular carcinoma patients.
Liu Y; Shen B; Huang T; Wang J; Jiang J
PLoS One; 2023; 18(7):e0288013. PubMed ID: 37406019
[TBL] [Abstract][Full Text] [Related]
28. Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma.
Hu B; Yang XB; Sang XT
J Hepatocell Carcinoma; 2020; 7():315-330. PubMed ID: 33204664
[TBL] [Abstract][Full Text] [Related]
29. Identification and functional analysis of lactic acid metabolism-related differentially expressed genes in hepatocellular carcinoma.
Li H; Qian F; Bao S
Front Genet; 2024; 15():1390882. PubMed ID: 38689649
[No Abstract] [Full Text] [Related]
30. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
[TBL] [Abstract][Full Text] [Related]
31. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
32. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.
Chen J; Wang H; Zhou L; Liu Z; Chen H; Tan X
Cancer Med; 2022 Dec; 11(24):5079-5096. PubMed ID: 35560794
[TBL] [Abstract][Full Text] [Related]
33. Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
Tang P; Qu W; Wang T; Liu M; Wu D; Tan L; Zhou H
Front Genet; 2021; 12():785185. PubMed ID: 34917132
[No Abstract] [Full Text] [Related]
34. Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma.
Li K; Yang Y; Ma M; Lu S; Li J
World J Surg Oncol; 2023 Jul; 21(1):216. PubMed ID: 37481543
[TBL] [Abstract][Full Text] [Related]
35. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
[TBL] [Abstract][Full Text] [Related]
36. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
37. Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma.
Shen B; Zhang G; Liu Y; Wang J; Jiang J
Genes (Basel); 2022 Oct; 13(10):. PubMed ID: 36292719
[TBL] [Abstract][Full Text] [Related]
38. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
[No Abstract] [Full Text] [Related]
39. Development and validation of a 14-gene signature for prognosis prediction in hepatocellular carcinoma.
Zhang BH; Yang J; Jiang L; Lyu T; Kong LX; Tan YF; Li B; Zhu YF; Xi AY; Xu X; Yan LN; Yang JY
Genomics; 2020 Jul; 112(4):2763-2771. PubMed ID: 32198063
[TBL] [Abstract][Full Text] [Related]
40. Identification of Hypoxia-Related Prognostic Signature and Competing Endogenous RNA Regulatory Axes in Hepatocellular Carcinoma.
Tang Y; Zhang H; Chen L; Zhang T; Xu N; Huang Z
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
